← All indications
Diphtheria
A localized infection of mucous membranes or skin caused by toxigenic strains of CORYNEBACTERIUM DIPHTHERIAE. It is characterized by the presence of a pseudomembrane at the site of infection. DIPHTHERIA TOXIN, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects.
Drugs by status
Approved for this indication (8)
Phase 4 trials (15)
- diphtheria, tetanus and whole cell pertussis vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- quinvaxem
- hepatitis a vaccine, inactivated
- attenuated measles vaccine - Edmonston strain
- Tetanus and diphtheria toxoids adsorbed
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- technetium tc-99m pentetate kit
- tetanus toxoid
- Inactivated polio virus - Enhanced
Phase 3 trials (25)
- 23-valent pneumococcal polysaccharide vaccine
- diphtheria, tetanus, and poliovirus vaccine
- diphtheria-tetanus-whole cell pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- menitorix
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- Measles, Mumps and Rubella Vaccine, Live
- rotavirus vaccine, live, oral, pentavalent
- tritanrix-hepb
- acellular pertussis vaccine
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- inactivated influenza vaccine
- live attenuated varicella vaccine
- pneumococcal 7-valent conjugate vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- polyribosil-ribitol-phosphate vaccine
- measles, mumps, rubella, varicella vaccine
- measles, mumps, and rubella vaccine
- hib-menac
- bivalent oral polio vaccine (bopv), type 1 and type 3
- polio, inactivated poliovirus vaccine
- human rotavirus, live attenuated
- Monovalent group C meningococcal vaccine
- Bivalent group A and C meningococcal vaccine
Phase 2 trials (6)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (25)
- Novo Nordisk
- Crucell
- Sanofi
- Sanofi-Aventis
- GlaxoSmithKline
- LG
- Shantha Biotechnics Limited
- Bandim Health Project
- National Institute of Allergy and Infectious Diseases (NIAID)
- Public Health England
- Swedish Institute for Infectious Disease Control
- Aarhus University
- University of London
- Harvard University
- Korea University
- Statens Serum Institut
- Tel Aviv University
- University of Copenhagen
- Leiden University
- Louisiana State University
- Medical Research Council, The Gambia
- Department of Health, United Kingdom
- Government of Norway
- Danish Council for Development Research
- Institute of Arthritis Research
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (4)
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (11)